DraftKings Inc vs Novavax Inc — how do they compare? DraftKings Inc trades at $25.7 (market cap $12.58B), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: DraftKings Inc is far larger — about 9.6× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals.
| DKNG | NVAX | |
|---|---|---|
Market Cap | $12.58B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $11.19 |
52-Week Low | $20.72 | $6.22 |
Enterprise Value | $13.51B | $889.30M |
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $25.65, up 5.69% on the day, with a bullish technical signal and strong analyst support. The company reported mixed Q2 2026 results, missing earnings estimates but showing robust prediction market growth. Revenue reached $6.05B in 2025, with positive net income of $3.71M, marking a significant turnaround from prior losses. Cash flow from operations improved to $662.86M, though net cash flow turned negative in 2026 projections.
The outlook is cautiously optimistic, driven by prediction market expansion and cost management, but risks include intense competition and promotional pressures. With a consensus price target of $34.00 and 73% buy ratings, upside potential exists if execution continues. Investors should weigh growth prospects against valuation premiums and earnings volatility.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Trailing returns across standard periods
Latest headlines on both assets
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →